2910 Seventh Street
36 articles with XOMA
XOMA Corporation announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab in participants with generalized myasthenia gravis.
XOMA Corporation announced it has earned a $1 million milestone payment from Agenus Inc. related to Merck’s advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer previously treated with anti-programmed cell death receptor ligand 1 therapy.
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results
Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone Rezolute’s financing resulted in accelerated $1.4 million payment Two partners presented early stage data at scientific conferences Acquired royalty interest in four lysosomal storage disorder enzymes being developed by Chiesi Group
In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference. The presentation will take place on Monday, September 14, 2020, at 2:00 PM ET. Cantor Fitzgerald Virtual Global Healthcare Conference. The presentation will take place on Tuesday, September 15, 2020, at 4:00 PM ET. Live webcasts of each
XOMA Reports Second Quarter 2020 Financial ResultsPartners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts
XOMA Corporation, announced its second quarter 2020 royalty asset portfolio advancements and financial results.
XOMA to Present at the 2020 Wedbush PacGrow Healthcare ConferenceLive video feed will be available on XOMA’s website
XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present a Company business update at the Wedbush PacGrow Virtual Healthcare Conference 2020.
XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000 ® and Russell 3000 ® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 26, 2020. “We expect XOMA’s addition to these Russell indexes will enhance the Company’s visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer of XOMA. The Russe
XOMA Corporation reported its first quarter 2020 financial results and provided a COVID-19 business update.
Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody
XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present an update about the Company’s business at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts.
XOMA Corporation reported its third quarter 2019 financial results.
Agenus Inc. cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation
The company burned through $1.2B and never brought a drug to market in its 37 years.
1/15/2018Here are three biopharma stocks worth keeping an eye on.
Dr. Datta and Mr. Hart will report to XOMA’s Chief Executive Officer, Jim Neal.
12/20/2017When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
12/18/2017Biotech stocks rocked in 2017, at least a lot of them did.
Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities under the license.
XOMA made important progress positioning the Company for long-term strategic success.